Tacrolimus and steroids versus ciclosporin microemulsion, steroids, and azathioprine in children undergoing liver transplantation: Randomised European multicentre trial

Deirdre Kelly, Paloma Jara, Burkhard Rodeck, Panayotis Lykavieris, Martin Burdelski, Michael Becker, Bruno Gridelli, Olivier Boillot, Javier Manzanares, Raymond Reding

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Background Results of studies in adult recipients of liver allograft suggest that tacrolimus is more efficacious than ciclosporin microemulsion in the prevention of acute rejection. We aimed to compare these drugs in children undergoing liver transplantation. Methods This 12-month multicentre, open-label, parallel-group, randomised study compared a dual tacrolimus regimen (tacrolimus/corticosteroids, n=93) with a triple ciclosporin microemulsion regimen (ciclosporin microemulsion/corticosteroids/azathioprine, n=92) in children who had had liver transplants (age ≤16 years, bodyweight ≤40 kg). Initial oral daily doses were 0·30 mg/kg for tacrolimus and 10 mg/kg for ciclosporin microemulsion. Primary endpoint was the incidence of and time to first histologically proven acute rejection. We excluded patients from analysis if they did not receive the study drug, or were given incorrect medication. Otherwise patients were analysed in accordance with their random treatment allocation, irrespective of whether they switched medication during the trial. Findings Median age was 22 months (IQR 9-56) in the tacrolimus group and 17 months (9-54) in the ciclosporin microemulsion group. We noted no difference between treatment groups with respect to patient survival (93·4% vs 92·2%; p=0·77) or graft survival (92·3% vs 85·4%; p=0·16) at month 12 after transplant. The acute rejection free rate at study end (Kaplan-Meier method) was 55·5% for patients on tacrolimus and 40·2% for patients on ciclosporin microemulsion (p=0·0288). The Kaplan-Meier estimate of patients free from corticosteroid-resistant acute rejection at study end was 94·0% for tacrolimus-treated patients and 70·4% for ciclosporin-microemulsion-treated patients (p

Original languageEnglish
Pages (from-to)1054-1061
Number of pages8
JournalLancet
Volume364
Issue number9439
DOIs
Publication statusPublished - Sep 18 2004

Fingerprint

Azathioprine
Tacrolimus
Liver Transplantation
Cyclosporine
Multicenter Studies
Steroids
Adrenal Cortex Hormones
Transplants
Liver
Kaplan-Meier Estimate
Graft Survival
Random Allocation
Pharmaceutical Preparations
Allografts
Survival
Incidence
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Tacrolimus and steroids versus ciclosporin microemulsion, steroids, and azathioprine in children undergoing liver transplantation : Randomised European multicentre trial. / Kelly, Deirdre; Jara, Paloma; Rodeck, Burkhard; Lykavieris, Panayotis; Burdelski, Martin; Becker, Michael; Gridelli, Bruno; Boillot, Olivier; Manzanares, Javier; Reding, Raymond.

In: Lancet, Vol. 364, No. 9439, 18.09.2004, p. 1054-1061.

Research output: Contribution to journalArticle

Kelly, D, Jara, P, Rodeck, B, Lykavieris, P, Burdelski, M, Becker, M, Gridelli, B, Boillot, O, Manzanares, J & Reding, R 2004, 'Tacrolimus and steroids versus ciclosporin microemulsion, steroids, and azathioprine in children undergoing liver transplantation: Randomised European multicentre trial', Lancet, vol. 364, no. 9439, pp. 1054-1061. https://doi.org/10.1016/S0140-6736(04)17060-8
Kelly, Deirdre ; Jara, Paloma ; Rodeck, Burkhard ; Lykavieris, Panayotis ; Burdelski, Martin ; Becker, Michael ; Gridelli, Bruno ; Boillot, Olivier ; Manzanares, Javier ; Reding, Raymond. / Tacrolimus and steroids versus ciclosporin microemulsion, steroids, and azathioprine in children undergoing liver transplantation : Randomised European multicentre trial. In: Lancet. 2004 ; Vol. 364, No. 9439. pp. 1054-1061.
@article{9e716c2735dd40efb08c42a7c38d76ae,
title = "Tacrolimus and steroids versus ciclosporin microemulsion, steroids, and azathioprine in children undergoing liver transplantation: Randomised European multicentre trial",
abstract = "Background Results of studies in adult recipients of liver allograft suggest that tacrolimus is more efficacious than ciclosporin microemulsion in the prevention of acute rejection. We aimed to compare these drugs in children undergoing liver transplantation. Methods This 12-month multicentre, open-label, parallel-group, randomised study compared a dual tacrolimus regimen (tacrolimus/corticosteroids, n=93) with a triple ciclosporin microemulsion regimen (ciclosporin microemulsion/corticosteroids/azathioprine, n=92) in children who had had liver transplants (age ≤16 years, bodyweight ≤40 kg). Initial oral daily doses were 0·30 mg/kg for tacrolimus and 10 mg/kg for ciclosporin microemulsion. Primary endpoint was the incidence of and time to first histologically proven acute rejection. We excluded patients from analysis if they did not receive the study drug, or were given incorrect medication. Otherwise patients were analysed in accordance with their random treatment allocation, irrespective of whether they switched medication during the trial. Findings Median age was 22 months (IQR 9-56) in the tacrolimus group and 17 months (9-54) in the ciclosporin microemulsion group. We noted no difference between treatment groups with respect to patient survival (93·4{\%} vs 92·2{\%}; p=0·77) or graft survival (92·3{\%} vs 85·4{\%}; p=0·16) at month 12 after transplant. The acute rejection free rate at study end (Kaplan-Meier method) was 55·5{\%} for patients on tacrolimus and 40·2{\%} for patients on ciclosporin microemulsion (p=0·0288). The Kaplan-Meier estimate of patients free from corticosteroid-resistant acute rejection at study end was 94·0{\%} for tacrolimus-treated patients and 70·4{\%} for ciclosporin-microemulsion-treated patients (p",
author = "Deirdre Kelly and Paloma Jara and Burkhard Rodeck and Panayotis Lykavieris and Martin Burdelski and Michael Becker and Bruno Gridelli and Olivier Boillot and Javier Manzanares and Raymond Reding",
year = "2004",
month = "9",
day = "18",
doi = "10.1016/S0140-6736(04)17060-8",
language = "English",
volume = "364",
pages = "1054--1061",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Lancet Publishing Group",
number = "9439",

}

TY - JOUR

T1 - Tacrolimus and steroids versus ciclosporin microemulsion, steroids, and azathioprine in children undergoing liver transplantation

T2 - Randomised European multicentre trial

AU - Kelly, Deirdre

AU - Jara, Paloma

AU - Rodeck, Burkhard

AU - Lykavieris, Panayotis

AU - Burdelski, Martin

AU - Becker, Michael

AU - Gridelli, Bruno

AU - Boillot, Olivier

AU - Manzanares, Javier

AU - Reding, Raymond

PY - 2004/9/18

Y1 - 2004/9/18

N2 - Background Results of studies in adult recipients of liver allograft suggest that tacrolimus is more efficacious than ciclosporin microemulsion in the prevention of acute rejection. We aimed to compare these drugs in children undergoing liver transplantation. Methods This 12-month multicentre, open-label, parallel-group, randomised study compared a dual tacrolimus regimen (tacrolimus/corticosteroids, n=93) with a triple ciclosporin microemulsion regimen (ciclosporin microemulsion/corticosteroids/azathioprine, n=92) in children who had had liver transplants (age ≤16 years, bodyweight ≤40 kg). Initial oral daily doses were 0·30 mg/kg for tacrolimus and 10 mg/kg for ciclosporin microemulsion. Primary endpoint was the incidence of and time to first histologically proven acute rejection. We excluded patients from analysis if they did not receive the study drug, or were given incorrect medication. Otherwise patients were analysed in accordance with their random treatment allocation, irrespective of whether they switched medication during the trial. Findings Median age was 22 months (IQR 9-56) in the tacrolimus group and 17 months (9-54) in the ciclosporin microemulsion group. We noted no difference between treatment groups with respect to patient survival (93·4% vs 92·2%; p=0·77) or graft survival (92·3% vs 85·4%; p=0·16) at month 12 after transplant. The acute rejection free rate at study end (Kaplan-Meier method) was 55·5% for patients on tacrolimus and 40·2% for patients on ciclosporin microemulsion (p=0·0288). The Kaplan-Meier estimate of patients free from corticosteroid-resistant acute rejection at study end was 94·0% for tacrolimus-treated patients and 70·4% for ciclosporin-microemulsion-treated patients (p

AB - Background Results of studies in adult recipients of liver allograft suggest that tacrolimus is more efficacious than ciclosporin microemulsion in the prevention of acute rejection. We aimed to compare these drugs in children undergoing liver transplantation. Methods This 12-month multicentre, open-label, parallel-group, randomised study compared a dual tacrolimus regimen (tacrolimus/corticosteroids, n=93) with a triple ciclosporin microemulsion regimen (ciclosporin microemulsion/corticosteroids/azathioprine, n=92) in children who had had liver transplants (age ≤16 years, bodyweight ≤40 kg). Initial oral daily doses were 0·30 mg/kg for tacrolimus and 10 mg/kg for ciclosporin microemulsion. Primary endpoint was the incidence of and time to first histologically proven acute rejection. We excluded patients from analysis if they did not receive the study drug, or were given incorrect medication. Otherwise patients were analysed in accordance with their random treatment allocation, irrespective of whether they switched medication during the trial. Findings Median age was 22 months (IQR 9-56) in the tacrolimus group and 17 months (9-54) in the ciclosporin microemulsion group. We noted no difference between treatment groups with respect to patient survival (93·4% vs 92·2%; p=0·77) or graft survival (92·3% vs 85·4%; p=0·16) at month 12 after transplant. The acute rejection free rate at study end (Kaplan-Meier method) was 55·5% for patients on tacrolimus and 40·2% for patients on ciclosporin microemulsion (p=0·0288). The Kaplan-Meier estimate of patients free from corticosteroid-resistant acute rejection at study end was 94·0% for tacrolimus-treated patients and 70·4% for ciclosporin-microemulsion-treated patients (p

UR - http://www.scopus.com/inward/record.url?scp=4544380236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4544380236&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(04)17060-8

DO - 10.1016/S0140-6736(04)17060-8

M3 - Article

C2 - 15380964

AN - SCOPUS:4544380236

VL - 364

SP - 1054

EP - 1061

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9439

ER -